Results 61 to 70 of about 1,721,925 (269)

Postmastectomy internal mammary nodal irradiation: A long-term outcome

open access: yesMedicina, 2014
Background and objective: The internal mammary lymph nodes (IMN) have been recognized as a potential site of regional breast cancer spread. The aim of this study was to evaluate the impact of internal mammary node radiotherapy (RT) to on clinical ...
Eduardas Aleknavičius   +3 more
doaj   +1 more source

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley   +6 more
wiley   +1 more source

Extracellular Vesicles as Tools for Crossing the Blood–Brain Barrier to Treat Lysosomal Storage Diseases

open access: yesLife
Extracellular vesicles (EVs) are nanosized, membrane-bound structures that have emerged as promising tools for drug delivery, especially in the treatment of lysosomal storage disorders (LSDs) with central nervous system (CNS) involvement.
Giovanni Lerussi   +6 more
doaj   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz   +7 more
wiley   +1 more source

Improvement of Sickle Cell Disease Care Mitigates the Healthcare Utilization Induced by Increased Prevalence: Experience of a Tertiary Pediatric Center

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure We aimed to assess
Maude Cigna   +16 more
wiley   +1 more source

Nanobiosensors for Rheumatoid Arthritis Biomarkers: Advances and Clinical Translational Potential

open access: yesInternational Journal of Nanomedicine
Xiaoyong Zhang, Xuewu Song, Mingyue Chen, Yifei Lei, Jinqi LiDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic ...
Zhang X, Song X, Chen M, Lei Y, Li J
doaj  

Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH)

open access: yesThe Annals of African Surgery, 2010
Background: The incidence of benign prostatic hyperplasia peaks 80% in old age. Bothersome symptoms and progression to acute urinary retention and need for surgery are important concerns.
Oliech J.S.
doaj  

BRD4 modulator ZL0580 and LEDGINs additively block and lock HIV-1 transcription

open access: yesNature Communications
The persistence of HIV-1 in a latent state within long-lived immune cells remains a major barrier to a cure for HIV-1 infection. The “block-and-lock” strategy aims to silence the HIV-1 provirus permanently using latency promoting agents (LPAs).
Eline Pellaers   +9 more
doaj   +1 more source

Drug therapy for double-hit lymphoma

open access: yesDrugs in Context, 2019
Double-hit lymphoma (DHL) is a rare type of aggressive B-cell lymphoma defined as a high-grade B-cell lymphoma (HGBCL) with the presence of MYC, BCL2 and/or BCL6 rearrangements.
Vania Phuoc   +2 more
doaj   +1 more source

Secretory Phospholipase A2 in Patients With Sickle Cell Disease Hospitalized for Vaso‐Occlusive Pain Episodes

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Secretory phospholipase A2 (sPLA2) is an inflammatory mediator linked to acute chest syndrome (ACS) in sickle cell disease (SCD), a serious complication that can develop during an acute vaso‐occlusive pain episode (VOE). Plasma sPLA2 levels have been proposed as a potential biomarker for predicting ACS onset.
Rawan Korman   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy